Table 1.

The roles of RNA m6A-regulated ferroptosis in various tumors

Types	Genes	Functions	Targets	Molecular regulatory mechanism	Tumor types	References
Writer	METTL14	Promote	SLC7A11	In hypoxic conditions, METTL14 inhibits ferroptosis in hepatocellular carcinoma cells through m6A-YTHDF2-mediated degradation of SLC7A11 mRNA at the 5'UTR, which in turn promotes tumor development	Hepatocellular carcinoma (HCC)	[171]
Writer	METTL14	Promote	FTH1	METTL14 reduces FTH1 mRNA stability through m6A methylation, thereby enhancing sorafenib-induced ferroptosis, which contributes to suppressing cervical cancer progression via the PI3K/Akt signaling pathway	Cervical cancer	[190]
Writer	METTL3	Inhibit	SLC7A11	In HB, METTL3-IGF2BP1 mediated m6A modification promotes the inhibition of CCR4-NOT complex-mediated adenylate deadenylation, which enhances SLC7A11 mRNA stability and expression and inhibits tumor ferroptosis	Hepatoblastoma (HB)	[172]
Writer	METTL3	Inhibit	FSP1	In NSCLC, miR-4443 inhibits cisplatin-induced ferroptosis by negatively regulating the level of METTL3-induced FSP1 m6A methylation, thereby conferring cisplatin resistance in NSCLC cells	Non-small cell lung cancer (NSCLC)	[179]
Writer	METTL3	Inhibit	FSP1	In glioma, the induction of fear stress resulted in an upregulation of METTL3, which increases the methylation level of FSP1 and stabilizes FSP1 mRNA and ultimately inhibits ferroptosis	Glioma	[180]
Writer	WTAP	Inhibit	NRF2	In bladder cancer, WTAP/YTHDF1 promotes cell viability of bladder cancer and inhibits erastin-induced ferroptosis by promoting the levels of the antioxidant factor NRF2 mRNA	Bladder cancer	[184]
Writer	METTL16	Inhibit	GPX4	In breast cancer, METTL16 promotes GPX4 expression through m6A modification, which inhibits cancer cell ferroptosis and promotes breast cancer progression	Breast cancer	[182]
Writer	METTL16	Inhibit	SENP3	METTL16 interacts with IGF2BP2 and enhances the stability of SENP3 mRNA, thereby inhibiting the lactoferrin degradation. Consequently, elevated lactoferrin expression contributes to the ferric chelation, thereby increasing the resistance of HCC cells to ferroptosis	Hepatocellular carcinoma (HCC)	[183]
Eraser	ALKBH5	Promote	SLC7A11	In NSCLC, ALKBH5 is identified to function as the tumor suppressor via m6A-mediated SLC7A11 mRNA and ferroptosis induction	Non-small cell lung cancer (NSCLC)	[173]
Eraser	FTO	Promote	SLC7A11	In PTC, FTO regulates PTC cell ferroptosis by mediating the m6A methylation of SLC7A11, which in turn promotes the degradation of SLC7A11 mRNA, thereby inducing ferroptosis and attenuating tumor migration and invasion	Papillary thyroid cancer (PTC)	[174]
Eraser	FTO	Inhibit	SLC7A11 and GPX4	Elevated FTO expression induced SLC7A11 and GPX4 expression through an m6A-YTHDF2-dependent mechanism to resist ferroptosis in CRC cells	Colorectal cancer (CRC)	[175]
Reader	YTHDC2	Promote	SLC3A2	YTHDC2 induces ferroptosis by inhibiting SLC7A11 and SLC3A2. YTHDC2-induced ferroptosis occurs via m6A-dependent mRNA degradation of HOXA13, which results in a subsequent reduction in SLC3A2 expression	Lung adenocarcinoma cells	[170]
Reader	NKAP	Inhibit	SLC7A11	In glioblastoma, NKAP inhibits tumor cell ferroptosis by recognizing methylation sites and recruiting the splicing factor SFPQ for the processing of SLC7A11 mRNA, thereby promoting mRNA maturation	Glioblastoma	[176]
Reader	IGF2BP3	Inhibit	GPX4, SLC3A2, ACSL3, and FTH1	In LUAD, the overexpression of IGF2BP3 inhibits ferroptosis by stabilizing the mRNAs of ferroptosis-resistant factors, such as GPX4, SLC3A2, ACSL3, and FTH1	Lung adenocarcinoma (LUAD)	[188]
Reader	IGF2BP3	Inhibit	NRF2	In HCC, IGF2BP3 inhibits sorafenib-induced ferroptosis by promoting NRF2 mRNA stability	Hepatocellular carcinoma (HCC)	[189]
Reader	IGF2BP2	Inhibit	FOXM1	The lnc RNA ABHD11-AS1 functions as a mediator to facilitate the interaction between IGF2BP2 and the E3 ubiquitin ligase TRIM21, thereby inhibiting ferroptosis and enhancing the stability of the transcription factor FOXM1, which in turn promotes tumor cell proliferation	Colorectal cancer (CRC)	[191]